Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Kreer C, et al. Among authors: rohde c. Cell. 2020 Aug 20;182(4):843-854.e12. doi: 10.1016/j.cell.2020.06.044. Epub 2020 Jul 13. Cell. 2020. PMID: 32673567 Free PMC article.
Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus.
Krähling V, Becker D, Rohde C, Eickmann M, Eroğlu Y, Herwig A, Kerber R, Kowalski K, Vergara-Alert J, Becker S; European Mobile Laboratory consortium. Krähling V, et al. Among authors: rohde c. Med Microbiol Immunol. 2016 Apr;205(2):173-83. doi: 10.1007/s00430-015-0438-6. Epub 2015 Oct 16. Med Microbiol Immunol. 2016. PMID: 26475282
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, Hesterkamp T, Jambrecina A, Borregaard S, Ly ML, Zinser ME, Bartels E, Poetsch JSH, Neumann R, Fux R, Schmiedel S, Lohse AW, Haagmans BL, Sutter G, Becker S, Addo MM. Koch T, et al. Among authors: rohde c. Lancet Infect Dis. 2020 Jul;20(7):827-838. doi: 10.1016/S1473-3099(20)30248-6. Epub 2020 Apr 21. Lancet Infect Dis. 2020. PMID: 32325037 Free PMC article. Clinical Trial.
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, Halwe S, Jeong Y, Park YS, Kim JO, Song M, Boyd A, Tran N, Silman D, Poulton I, Datoo M, Marshall J, Themistocleous Y, Lawrie A, Roberts R, Berrie E, Becker S, Lambe T, Hill A, Ewer K, Gilbert S. Folegatti PM, et al. Among authors: rohde c. Lancet Infect Dis. 2020 Jul;20(7):816-826. doi: 10.1016/S1473-3099(20)30160-2. Epub 2020 Apr 21. Lancet Infect Dis. 2020. PMID: 32325038 Free PMC article. Clinical Trial.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Folegatti PM, et al. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702298 Free PMC article. Clinical Trial.
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Kreer C, et al. Among authors: rohde c. Cell. 2020 Sep 17;182(6):1663-1673. doi: 10.1016/j.cell.2020.08.046. Cell. 2020. PMID: 32946786 Free PMC article. No abstract available.
Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies.
Krähling V, Halwe S, Rohde C, Becker D, Berghöfer S, Dahlke C, Eickmann M, Ercanoglu MS, Gieselmann L, Herwig A, Kupke A, Müller H, Neubauer-Rädel P, Klein F, Keller C, Becker S. Krähling V, et al. Among authors: rohde c. J Immunol Methods. 2021 Mar;490:112958. doi: 10.1016/j.jim.2021.112958. Epub 2021 Jan 4. J Immunol Methods. 2021. PMID: 33412174 Free PMC article.
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, Limpinsel L, Okba NMA, Bošnjak B, Sandrock I, Odak I, Halwe S, Sauerhering L, Brosinski K, Liangliang N, Duell E, Jany S, Freudenstein A, Schmidt J, Werner A, Gellhorn Serra M, Klüver M, Guggemos W, Seilmaier M, Wendtner CM, Förster R, Haagmans BL, Becker S, Sutter G, Volz A. Tscherne A, et al. Among authors: rohde c. Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):e2026207118. doi: 10.1073/pnas.2026207118. Proc Natl Acad Sci U S A. 2021. PMID: 34162739 Free PMC article.
441 results